Potential New Treatment for Sickle Cell Illness

Recently, a group of medical professionals declared that patients receiving a novel gene editing treatment for sickle cell disease could safely proceed. By targeting the disease’s genetic origin, the medication may offer a novel remedy. A genetic blood condition known as sickle cell disease (SCD) affects millions of people worldwide. The illness is widespread in regions like Africa and India where malaria incidence are high. More than any other group, it affects Black Americans, African Americans, and people from the Middle East. Researchers think having SCD may help shield against severe malaria.

Unhealthy blood cells carried by those with sickle cell disease (SCD) can cause obstructions known as blood clots. The human body’s bones and organs may be harmed by this and experience pain. Many children with the most severe form of the condition pass away before turning five, usually as a result of an infection or significant blood loss, according to the World Health Organization. “Exa-cel” is the new medicine developed by CRISPR Therapeutics and Vertex Pharmaceuticals. The patient’s blood cells’ DNA is permanently altered as part of the treatment. Assisting the body in producing healthy red blood cells again is the aim. While healthy blood cells are present from birth, sickle cell disease patients start to generate defective blood cells.

After patients receive the treatment, the switching gene is deleted using the gene-editing technology CRISPR after stem cells are extracted from their blood. After receiving medication to eradicate additional damaged red blood cells, patients receive their modified stem cells back. Vertex stated that 46 participants in the study received the medication. Of the thirty who underwent at least eighteen months of surveillance, twenty-nine experienced no pain crises for a minimum of a year. Vertex said that none of the 30 people spent that much time in the hospital due to pain crises.

The first patient to test the “exa-cel” treatment was Victoria Gray from Mississippi. Gray disclosed to scientists that she had experienced agony since childhood during a scientific meeting earlier this year. The day she received the procedure, she spoke of feeling “reborn.” She said, “My kids don’t worry about losing their mom to sickle cell disease anymore.” In a trial including SCD patients, the U.S. Food and Drug Administration (FDA) had already determined that the treatment was beneficial. However, the health ministry was unsure if the study’s limited genetic sample size adequately represented the total American population for sickle cell disease.

Be the first to comment

Leave a Reply

Your email address will not be published.


*